World Pharma News

Business & Industry News Channel

Bristol-Myers Squibb's Opdivo (nivolumab) receives expanded FDA approval in previously-treated metastatic non-small cell lung cancer (NSCLC)

Bristol-Myers SquibbBristol-Myers Squibb Company (NYSE:BMY) announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection, for intravenous use, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR mutation or ALK translocation should have disease progression on appropriate targeted therapy prior to receiving Opdivo.

Hits: 77

Read more ...

Roche's ocrelizumab first investigational medicine to show positive pivotal study results in both relapsing and primary progressive forms of multiple sclerosis

RocheRoche (SIX: RO, ROG; OTCQX: RHHBY) has announced data from three positive, pivotal Phase III studies of ocrelizumab in people with relapsing multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS). Data from two identical studies (called OPERA I and OPERA II) in people with relapsing MS, which affects approximately 85 percent of people with MS at the time of diagnosis, showed ocrelizumab was superior to interferon beta-1a (Rebif®), a well-established MS therapy, in reducing the three major markers of disease activity over the two-year controlled treatment period.

Hits: 198

Read more ...

Johnson & Johnson announces completion of Cordis divestiture to Cardinal Health

Johnson & JohnsonJohnson & Johnson (NYSE: JNJ) has announced the completion of the divestiture of its Cordis business to Cardinal Health for an approximate value of $2 billion, subject to customary adjustments. The Cordis business is a global leader in the development and manufacture of interventional vascular technology and generated net revenues of approximately $780 million in 2014.

Hits: 246

Read more ...

Long-term efficacy of Gilenya® reinforced by new 'no evidence of disease activity' (NEDA-4) analysis in MS patients over seven years

NovartisNovartis announced today a new analysis from the phase III FREEDOMS and FREEDOMS II trials reinforcing the long-term efficacy profile of Gilenya® (fingolimod). The analysis evaluated the proportion of Gilenya patients with relapsing multiple sclerosis (RMS) achieving 'no evidence of disease activity' (NEDA-4) every year over seven years[1].

Hits: 242

Read more ...

Pfizer completes acquisition of Nimenrix and Mencevax from GlaxoSmithKline

PfizerPfizer Inc. (NYSE:PFE) has completed the acquisition of GlaxoSmithKline’s quadrivalent meningococcal ACWY vaccines Nimenrix and Mencevax. "The addition of Nimenrix and Mencevax helps us to fulfill our vision to protect lives with innovative vaccines to fight serious diseases worldwide," said Susan Silbermann, president and general manager, Pfizer Vaccines.

Hits: 284

Read more ...

Genzyme introduces "vs.MS," a global initiative aimed at uncovering the often unspoken challenges of MS to drive better informed care

GenzymeGenzyme, a Sanofi company, today announced a new global initiative, vs.MS, that is designed to raise awareness of the often unspoken emotional and physical burden of relapsing multiple sclerosis (RMS) on people living with the disease and their care partners. To better understand the full burden associated with RMS, Genzyme fielded a global survey among more than 1,500 people living with RMS and their care partners across seven countries.

Hits: 316

Read more ...

New England Journal of Medicine publishes results of head-to-head studies of brodalumab versus ustekinumab in psoriasis

AstraZenecaThe New England Journal of Medicine (NEJM) has published positive results from two pivotal, multi-centre, Phase III studies - AMAGINE-2 and AMAGINE-3 - demonstrating that treatment with brodalumab resulted in significant clinical improvements in patients with moderate to severe psoriasis and was superior to both placebo and ustekinumab, a leading approved treatment for psoriasis.

Hits: 449

Read more ...

© World Pharma News 2006 - 2015

Top Desktop version